Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joseph Ciaffoni - President, CEO & Director Colleen Tupper - EVP & CFO Scott Dreyer - EVP & Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler & Co. David Steinberg - Jefferies John Boyle - William Blair & Company Rohit Bhasin - Needham & Company Gregory Fraser - Truist Securities Oren Livnat - H.C. Wainwright & Co. Operator Gr ...

August 5, 2021 Collegium Pharmaceutical, Inc. Q2 2021 Earnings Report Forward‐Looking Statements and use of Non‐GAAP Financial Measures | --- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State or ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations Joe Ciaffoni - President & Chief Executive Officer Paul Brannelly - Executive Vice President & Chief Financial Officer Scott Dreyer - Executive Vice President & Chief Commercial Officer Conference Call Participants Tim Lugo - William Blair David Steinberg - Jefferies David Amsellem - Piper Sandler Gregg Gilbert - Truist Securities Serge Belanger ...

Table of Contents Smaller reporting company ☐ Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of reg ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations Joe Ciaffoni - Chief Executive Officer Paul Brannelly - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Jaffray Lachlan Hanbury-Brown - William Blair Serge Belanger - Needham & Company Brandon Folkes - Cantor Fitzgerald Kevin Kedra - G. Research Operator Greetings, and welc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State or other jurisdiction of ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2020 Earnings Conference Call November 6, 2020 4:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations Joe Ciaffoni - Chief Executive Officer Paul Brannelly - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Lachlan Hanbury-Brown - William Blair Greg Fraser - Truist Securities Serge Belanger - Needham & Company David Steinberg - Jefferies Brandon Folkes - Cantor Fitzg ...

Table of Contents Smaller reporting company ☐ Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joseph Ciaffoni - President, CEO & Director Paul Brannelly - EVP & CFO Scott Dreyer - EVP & Chief Commercial Officer Conference Call Participants David Steinberg - Jefferies Gregory Gilbert - Truist Securities Serge Belanger - Needham & Company Brandon Folkes - Cantor Fitzgerald & Co. Dana Flanders - Guggenheim Securities David Amsellem - Piper Sandler & Co. Op ...